证券代码：300981 证券简称：中红医疗 公告编号：2025-020 二、会议审议情况 1. 审议通过《关于〈2024 年度监事会工作报告〉的议案》 2024 年度，公司监事会按照《公司法》《公司章程》赋予的各项职责，贯彻 落实股东大会的各项决议，规范公司治理。全体监事勤勉尽责，落实监督职责， 认真审议了各项监事会议案，切实维护了公司及全体股东利益。 中红普林医疗用品股份有限公司 第四届监事会第六次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开情况 中红普林医疗用品股份有限公司（以下简称"公司"）第四届监事会第六次 （定期）会议于 2025 年 4 月 22 日以现场和通讯相结合方式召开，2025 年 4 月 12 日公司以电话和电子邮件方式向全体监事发出会议通知。会议应参加表决的 监事 3 人，实际参加表决监事 3 人，会议由监事会主席周朝华先生主持。会议的 召集、召开符合相关法律、法规和公司章程的规定。 表决结果为：同意 3 票，反对 0 票，弃权 0 票。 本议案尚需提交公司 2024 年年度股东大会审议。 本议案尚需提交公 ...

证券代码：300981 证券简称：中红医疗 公告编号：2025-019 中红普林医疗用品股份有限公司 第四届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开情况 中红普林医疗用品股份有限公司（以下简称"公司"）第四届董事会第七次 （定期）会议于 2025 年 4 月 22 日以现场和通讯相结合方式召开，2025 年 4 月 12 日公司以电话和电子邮件方式向全体董事发出会议通知。会议应参加表决的 董事 9 人，实际参加表决董事 9 人，会议由董事长桑树军先生主持，公司监事、 高管和相关人员列席了会议。会议的召集、召开符合相关法律、法规和公司章程 的规定。 二、会议审议情况 1. 审议通过《关于〈2024 年度总经理工作报告〉的议案》 经审议，董事会认为 2024 年度公司以总经理为代表的管理层有效、充分地 执行了股东大会、董事会的各项决议，该报告客观、真实地反映了管理层 2024 年度主要工作。 表决结果为：同意 9 票，反对 0 票，弃权 0 票。 2. 审议通过《关于〈2024 年度董事会工作报告〉的议案》 2024 ...

证券代码：300981 证券简称：中红医疗 公告编号：2025-026 中红普林医疗用品股份有限公司 关于 2024 年度利润分配及资本公积金转增股本预案的公 告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 中红普林医疗用品股份有限公司（以下简称"公司"）于 2025 年 4 月 22 日 召开第四届董事会第七次（定期）会议和第四届监事会第六次（定期）会议，审 议通过了《关于 2024 年度利润分配及资本公积金转增股本预案的议案》，本预 案尚需提交公司 2024 年年度股东大会审议，并在股东大会审议通过后两个月内 实施。现将相关情况公告如下： 一、利润分配预案基本情况 （一）利润分配预案的具体内容 经容诚会计师事务所（特殊普通合伙）审计，截至 2024 年 12 月 31 日，公 司合并报表未分配利润金额为 3,286,683,752.02 元，母公司未分配利润金额为 2,915,131,157.63 元。结合公司自身发展阶段和资金需求，综合考量对股东的 合理回报并兼顾公司的可持续发展，公司董事会建议 2024 年度的利润分配预案 为：以公司实施利润分配方 ...

证券代码：300981 证券简称：中红医疗 公告编号：2025-027 中红普林医疗用品股份有限公司 关于提请股东大会授权董事会办理以简易程序向特定对象 发行股票的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 根据《上市公司证券发行注册管理办法》（以下简称《注册管理办法》）《深 圳证券交易所上市公司证券发行上市审核规则》《深圳证券交易所上市公司证券 发行与承销业务实施细则》等相关规定，中红普林医疗用品股份有限公司（以下 简称"公司"）于 2025 年 4 月 22 日召开第四届董事会第七次（定期）会议，审 议通过了《关于提请股东大会授权董事会办理以简易程序向特定对象发行股票的 议案》，同意公司董事会提请股东大会授权董事会决定以简易程序向特定对象发 行融资总额不超过人民币三亿元且不超过最近一年末净资产百分之二十的股票， 授权期限为 2024 年度股东大会通过之日起至 2025 年度股东大会召开之日止。本 事项需提交公司 2024 年年度股东大会审议。现将相关情况公告如下： 一、授权具体内容 1. 确认公司是否符合以简易程序向特定对象发行股票的条件 授权董 ...

Financial Performance - The company's revenue for Q1 2025 reached ¥629,149,972.58, representing a 15.45% increase compared to ¥544,935,917.11 in the same period last year[5]. - Net profit attributable to shareholders was ¥18,921,091.71, a significant increase of 1,369.95% from ¥1,287,194.84 in the previous year[5]. - The net profit after deducting non-recurring gains and losses was ¥11,371,210.65, compared to a loss of ¥17,660,522.98 in the same period last year, marking a 164.39% improvement[5]. - The basic earnings per share rose to ¥0.0487, up 1,375.76% from ¥0.0033 in the previous year[5]. - Total operating revenue for Q1 2025 reached CNY 629,149,972.58, an increase of 15.4% compared to CNY 544,935,917.11 in the same period last year[20]. - Net profit for the period was CNY 19,347,161.25, significantly higher than CNY 1,379,353.57 in Q1 2024, marking an increase of 1,403.5%[21]. - The company reported a gross profit margin of approximately 2.6% for the quarter, compared to 1.5% in the previous year[20]. - Total comprehensive income amounted to CNY 19,093,464.17, with CNY 18,667,394.63 attributable to the parent company[22]. - Basic and diluted earnings per share were both CNY 0.0487, compared to CNY 0.0033 in the previous period, reflecting a significant increase[22]. Assets and Liabilities - The total assets at the end of the reporting period were ¥7,429,579,726.43, reflecting a 2.76% increase from ¥7,230,360,796.53 at the end of the previous year[5]. - The company's total assets increased to CNY 7,429,579,726.43 from CNY 7,230,360,796.53, representing a growth of 2.8%[18]. - Current liabilities rose to CNY 1,325,006,781.55, compared to CNY 1,236,429,413.12, indicating an increase of 7.2%[18]. - Non-current liabilities increased to CNY 464,793,880.80 from CNY 373,245,783.49, reflecting a growth of 24.5%[18]. - The company’s total liabilities decreased by 53.62% in current non-current liabilities, from ¥148,666,729.22 to ¥68,954,115.56, primarily due to the repayment of long-term loans[9]. Cash Flow - The net cash flow from operating activities was negative at -¥11,381,842.34, a decline of 134.07% compared to a positive cash flow of ¥33,406,639.56 in the same period last year[5][10]. - Cash inflow from operating activities totaled CNY 643,690,531.79, an increase from CNY 587,357,838.16 year-over-year[24]. - Cash outflow from operating activities increased to CNY 655,072,374.13 from CNY 553,951,198.60, indicating higher operational costs[25]. - Net cash flow from investing activities was CNY 246,929,792.82, up from CNY 196,142,729.39 in the previous period[25]. - The company reported a cash inflow from financing activities of CNY 504,900,000.00, down from CNY 749,788,000.00 in the previous period[25]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 20,072[12]. - The largest shareholder, Zhonghong Pulin Group Co., Ltd., holds 45.00% of the shares, totaling 175,500,000 shares[12]. - The company has a total of 32,572,800 restricted shares held by executive shareholders, which are subject to lock-up rules[14]. - The company has not reported any changes in the participation of major shareholders in margin financing and securities lending activities[12]. - There are no new developments regarding preferred shareholders or changes in restricted shares during the reporting period[13]. Operational Insights - The company experienced an 84.89% decrease in other income, dropping from ¥8,923,506.19 to ¥1,348,556.76, mainly due to a reduction in government subsidies[10]. - The company reported a significant decrease in financial expenses by 35.09%, from -¥14,856,106.59 to -¥9,643,486.00, primarily due to reduced interest income and exchange gains[10]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[19]. - Research and development expenses for the quarter were CNY 11,499,945.08, up from CNY 9,612,140.03, which is an increase of 19.6%[21]. Inventory and Receivables - The total accounts receivable rose to approximately ¥461.68 million, up from ¥427.48 million, indicating an increase of 7.99%[16]. - Inventory levels increased to approximately ¥682.51 million from ¥576.39 million, reflecting a growth of 18.38%[16]. - The total trading financial assets at the end of the period were approximately ¥1.76 billion, slightly up from ¥1.73 billion, showing an increase of 1.67%[16].

Financial Performance - The company reported a loss due to impairment provisions for goodwill and fixed assets, despite no significant adverse changes in core business and competitive strength[3]. - The company's operating revenue for 2024 reached ¥2,456,650,714.86, representing a 16.69% increase compared to ¥2,105,249,607.06 in 2023[17]. - The net profit attributable to shareholders for 2024 was -¥87,128,895.94, an improvement of 33.42% from -¥130,870,579.41 in 2023[17]. - The net cash flow from operating activities significantly increased by 340.94% to ¥183,912,342.98 in 2024, compared to ¥41,708,735.81 in 2023[17]. - The total assets of the company as of the end of 2024 were ¥7,230,360,796.53, a 2.46% increase from ¥7,056,973,990.05 at the end of 2023[17]. - The company's net assets attributable to shareholders decreased by 5.10% to ¥5,474,102,359.07 at the end of 2024, down from ¥5,768,086,190.12 in 2023[17]. - The basic earnings per share improved by 35.29% to -¥0.22 in 2024, compared to -¥0.34 in 2023[17]. - The company reported a quarterly operating revenue of ¥689,837,865.07 in Q3 2024, with a net profit attributable to shareholders of ¥18,502,436.81[20]. - Non-recurring gains and losses totaled ¥56,334,402.50 in 2024, down from ¥84,774,962.03 in 2023[23]. - The company achieved a gross profit margin of 13.37% in the medical device industry, with a year-on-year increase of 1.27%[79]. Product Development and Innovation - The company plans to continue focusing on market expansion and new product development to enhance future performance[26]. - The company is actively involved in the research and development of new technologies, including AI and big data applications in healthcare[30]. - The company has developed a diverse range of glove products, including polyisoprene gloves, which are produced by only a few companies globally due to high technical barriers[36]. - The company is focused on expanding its product line with innovative technologies, including a new injection pump with a 4.3-inch color touch display[57]. - The company is developing multiple new products, including the DS90 infusion information collection system and SP92D dual-channel infusion pump, both aimed at global sales[89]. - The company is expanding its product offerings in the medical device sector, particularly in disposable and sterilized products[92]. - The company has a pipeline of new products aimed at enhancing its market position in the medical device industry[92]. - The company is committed to maintaining transparency with investors regarding the progress of procurement projects and potential impacts on financial performance[95]. Market Trends and Industry Outlook - The global healthcare market is experiencing stable growth, driven by increasing health awareness and improved medical security systems, with significant policy support for medical technology development[28]. - The global nitrile and PVC glove market is showing signs of recovery, with domestic manufacturers experiencing sufficient orders despite short-term price fluctuations due to tariffs on medical gloves[34]. - Natural latex gloves are facing declining demand in 2023, but the market is expected to stabilize as demand for surgical gloves increases in 2024[35]. - The global market for infusion pumps is projected to reach approximately $11.2 billion in 2022, with an expected growth to $18.92 billion by 2027[40]. - The safety infusion products market in China is experiencing stable growth, with a significant focus on high-end, intelligent, and safe medical consumables[38]. Strategic Initiatives and Future Plans - The company plans to enhance competitiveness through cost reduction, efficiency improvement, continuous R&D, and investment mergers and acquisitions[3]. - The company aims to become a leading manufacturer of high-end precision infusion products through acquisitions and product line expansions in the safety infusion division[47]. - The company is exploring potential acquisitions to bolster its product portfolio, with a budget of 300 million allocated for this purpose[177]. - The company plans to enhance its R&D capabilities by integrating technologies from Hengbao Health and developing new product lines using big data and AI[138]. - The company intends to strengthen its sales team for non-US international markets and increase its domestic market share[137]. Governance and Compliance - The company has maintained a robust governance structure, ensuring compliance with relevant laws and regulations, and has not encountered any legal violations during the reporting period[153]. - The company conducted four shareholder meetings during the reporting period, ensuring all procedures complied with legal requirements and facilitated participation from minority shareholders[154]. - The board of directors consists of 9 members, including 3 independent directors, and has held 8 meetings during the reporting period[156]. - The company has established a complete and independent financial management system, with no shared bank accounts with the controlling shareholder[166]. - The company has a governance structure that ensures independence from its controlling shareholder, with no interference in decision-making or operations[155]. Financial Management and Investment - The company has established a risk management system for derivatives trading, including clear trading principles and risk control measures[113]. - The company plans to use its own funds for derivatives trading, ensuring no involvement of raised funds[113]. - The company has implemented a fundraising management method to ensure the proper use and supervision of raised funds[118]. - The company plans to engage in foreign exchange derivative trading and commodity futures hedging, reflecting a proactive risk management approach[189]. - The company has a total of 390,007,800 shares, with the dividend distribution based on the total shares minus those in the repurchase account[197]. Employee and Stakeholder Relations - The company has a market-oriented salary adjustment mechanism, focusing on a fair and competitive compensation system to motivate employees[194]. - The company has conducted a systematic training program for employees, including both online and offline training methods to enhance efficiency[195]. - The company emphasizes the importance of internal training and encourages employees to pursue further education and professional qualifications[196]. - The company has a total of 43,430,400 shares held by the chairman, with no changes during the reporting period[171]. Risk Factors and Challenges - The company faces risks from international market fluctuations, particularly due to geopolitical factors affecting trade and tariffs[141]. - The company is actively expanding its global production layout to mitigate the impact of international political changes on its market[142]. - Rising production costs, including raw materials, energy, and labor, pose a risk to the company's profitability, prompting efforts to optimize product formulations and enhance supply chain efficiency[146]. - The company primarily sells its protective gloves in overseas markets, with sales mainly settled in USD, making it vulnerable to exchange rate fluctuations that could impact its operating performance[144].

最新一期业绩显示，2024年三季报，公司实现营业收入18.38亿元，同比16.22%；净利润5103.23万元， 同比454.87%，销售毛利率12.86%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)10中红医疗-46.74-31.800.7441.61亿行业平均 44.5846.754.6999.90亿行业中值28.5527.772.1941.61亿1硕世生物-1692.50-1692.501.0634.97亿2诺唯 赞-515.13-515.132.2287.58亿3博晖创新-345.95-213.003.8153.10亿4康泰医学-258.4530.322.6450.27亿5华 大基因-188.97206.701.95192.03亿6奥精医疗-104.74-104.741.3318.98亿7睿昂基因-72.49-72.491.1310.48亿 8华大智造-52.56-52.563.94314.89亿9热景生物-48.54-48.542.6787.00亿11天智航-39.67-39.674.1448.84亿 4月8日，中红医疗今日收盘10.67元，上涨3.39%，最新市净率0.74，总市值4 ...

3月31日，中红医疗今日收盘11.96元，下跌3.39%，最新市净率0.83，总市值46.64亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)9中红医疗-52.39-35.640.8346.64亿行业平均 44.7248.614.80106.45亿行业中值32.5930.082.4746.64亿1硕世生物-1914.42-1914.421.2039.55亿2诺唯 赞-568.93-568.932.4696.73亿3博晖创新-292.72-180.233.2244.93亿4康泰医学-284.2833.352.9055.29亿5华 大基因-215.44235.662.23218.93亿6奥精医疗-118.65-118.651.5121.50亿7睿昂基因-81.14-81.141.2611.74亿 8华大智造-54.40-54.404.08325.92亿10热景生物-49.28-49.282.7188.33亿11天智航-45.30-45.304.7355.77亿 来源：金融界 股东方面，截至2024年9月30日，中红医疗股东户数20541户，较上次增加871户，户均持股市值35.28万 元，户均持股数 ...

最新一期业绩显示，2024年三季报，公司实现营业收入18.38亿元，同比16.22%；净利润5103.23万元， 同比454.87%，销售毛利率12.86%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)10中红医疗-54.40-37.010.8648.44亿行业平均 45.1449.524.84107.93亿行业中值31.9931.002.4848.44亿1硕世生物-1949.53-1949.531.2340.28亿2诺唯 赞-562.38-562.382.4395.62亿3利德曼-363.03174.161.5426.71亿4博晖创新-300.71-185.143.3146.15亿5康泰 医学-292.3334.302.9956.86亿6华大基因-221.13241.882.29224.71亿7奥精医疗-121.20-121.201.5421.96亿8 睿昂基因-82.72-82.721.2911.96亿9华大智造-55.10-55.104.14330.13亿11天智航-46.36-46.364.8457.07亿 中红医疗收盘上涨1.22%，最新市净率0.86，总市值 48.44亿元 3月26日 ...

中红普林医疗用品股份有限公司 关于子公司江西科伦医疗器械制造有限公司完成医疗器械 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 中红普林医疗用品股份有限公司（以下简称"公司"）子公司江西科伦医疗 器械制造有限公司于近期取得国家药品监督管理局颁发的《中华人民共和国医疗 器械注册证》，上述注册证为原有产品的延续注册，该注册证有效期限由原 2025 年 12 月 7 日到期变更为 2030 年 12 月 7 日到期。该项注册证具体情况如下： 证券代码：300981 证券简称：中红医疗 公告编号：2025-018 延续注册的公告 三、备查文件 1. 《中华人民共和国医疗器械注册证》（编号：国械注准 20153141772）。 特此公告。 中红普林医疗用品股份有限公司 一、基本信息 | 注册人名称 | 产品名称 | 注册证编号 | 注册分类 | | | 注册证有效期 | | | | 适用范围 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 江西科伦医 疗器械制造 | 一次性 ...